10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2022 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 17, 2023) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Net Sales | $ 43,653 | 43,075 | 34,608 |
| Cost of products sold, excluding amortization of intangible assets | 19,142 | 18,537 | 15,003 |
| Amortization of intangible assets | 2,013 | 2,047 | 2,132 |
| Research and development | 2,888 | 2,742 | 2,420 |
| Selling, general and administrative | 11,248 | 11,324 | 9,696 |
| Total Operating Cost and Expenses | 35,291 | 34,650 | 29,251 |
| Operating Earnings | 8,362 | 8,425 | 5,357 |
| Interest expense | 558 | 533 | 546 |
| Interest income | (183) | (43) | (46) |
| Net foreign exchange (gain) loss | 2 | 1 | (8) |
| Other (income) expense, net | (321) | (277) | (103) |
| Earnings from Continuing Operations Before Taxes | 8,306 | 8,211 | 4,968 |
| Taxes on Earnings from Continuing Operations | 1,373 | 1,140 | 497 |
| Earnings from Continuing Operations | 6,933 | 7,071 | 4,471 |
| Net Earnings from Discontinued Operations, net of taxes | 0 | 0 | 24 |
| Net Earnings | 6,933 | 7,071 | 4,495 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 3.94 | 3.97 | 2.51 |
| Discontinued Operations (in dollars per share) | 0.00 | 0.00 | 0.01 |
| Net Earnings (in dollars per share) | 3.94 | 3.97 | 2.52 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 3.91 | 3.94 | 2.49 |
| Discontinued Operations (in dollars per share) | 0.00 | 0.00 | 0.01 |
| Net Earnings (in dollars per share) | 3.91 | 3.94 | 2.50 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,753 | 1,775 | 1,773 |
| Dilutive Common Stock Options (in shares) | 11 | 14 | 13 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | 1,764 | 1,789 | 1,786 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 3 | 0 | 9 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |